Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Agios Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Agios Pharmaceuticals stockholders approved an amendment to the 2023 Stock Incentive Plan on June 18, 2026, increasing available shares by 2,000,000 for equity compensation, signaling the company's commitment to employee retention and alignment with shareholder value creation.
Key Takeaways
2,000,000 additional shares authorized under the 2023 Stock Incentive Plan for employee compensation
Amendment includes specific provision for same increase in incentive stock options availability
2 more takeaways